Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trialMassimo Cristofanilli, Dennis J. Slamon, Nicholas C. Turner et al.|The Lancet Oncology|2016Cited by 1.8k
Palbociclib in Hormone-Receptor–Positive Advanced Breast CancerNicholas C. Turner, Massimo Cristofanilli, Jungsil Ro et al.|New England Journal of Medicine|2015Cited by 1.6k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast CancerNicholas C. Turner, Massimo Cristofanilli, Dennis J. Slamon et al.|New England Journal of Medicine|2018Cited by 1.3k
The Landscape of Targeted Therapies in TNBCElena Vagia, Massimo Cristofanilli|Cancers|2020Cited by 448
Circulating giant macrophages as a potential biomarker of solid tumorsDaniel L. Adams, Massimo Cristofanilli|Proceedings of the National Academy of Sciences|2014Cited by 278